More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$502977444
EPS
-1.49
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
0.92529
Previous close
$13.31
Today's open
$13.50
Day's range
$13.10 - $14.25
52 week range
$5.78 - $19.40
show more
CEO
Christopher T. Giordano
Employees
6
Headquarters
Chapel Hill, NC
Exchange
NASDAQ Capital Market
Shares outstanding
37423917
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Company expects to report topline data from Phase 3 LEVEL clinical trial in August 2026 CHAPEL HILL, N.C., July 31, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) today reported financial results for the quarter ended June 30, 2026 and provided an update on its corporate progress.
GlobeNewsWire • Jul 31, 2026

Wall Street Analysts Predict a 121.36% Upside in Tenax Therapeutics (TENX): Here's What You Should Know
The mean of analysts' price targets for Tenax Therapeutics (TENX) points to a 121.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks Investment Research • Jul 21, 2026

Tenax Therapeutics: 'Hold' TNX-103 Data August 2026 - But With Caution Ahead
Tenax Therapeutics, Inc. is downgraded from Buy to Hold ahead of a major August 2026 phase 3 data readout for TNX-103 in PH-HFpEF. TNX-103 targets a large, unmet market with no approved therapies, but phase 3 success is uncertain despite promising phase 2 secondary endpoint results relating to 6MWD. The phase 3 LEVEL study is powered >90% to detect a 25-meter 6MWD change, but failure could cut TENX shares by 50% or more.
Seeking Alpha • Jul 6, 2026

Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026
Abstract recently submitted in anticipation of initial data analysis ahead of ESC Company expects to report topline LEVEL results in August CHAPEL HILL, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) announced today that results from the Phase 3 LEVEL clinical trial will be presented in a Late-Breaking Clinical Science session at the European Society of Cardiology (ESC) Congress 2026, being held August 28-31 in Munich, Germany.
GlobeNewsWire • Jul 2, 2026

Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHAPEL HILL, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced it awarded inducement option awards on July 1, 2026 as material inducements to the employment of three non-executive individuals newly hired by the Company in various accounting, clinical operations, and CMC/product development roles.
GlobeNewsWire • Jul 2, 2026

Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
On track to report topline data from Phase 3 LEVEL study of TNX-103 in third quarter of 2026 Global Phase 3 LEVEL-2 clinical trial ongoing, enrollment completion anticipated by end of 2027 Strengthened leadership team with appointments of Thomas Staab as Chief Financial Officer and Timothy Healey, MBA, as Chief Commercial Officer CHAPEL HILL, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, reported today financial results for the quarter ended March 31, 2026 and provided an update on its recent corporate progress.
GlobeNewsWire • May 12, 2026

Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer
Mr. Healey is a seasoned pharmaceutical executive with a strong track record of successful commercial leadership experience Mr. Healey is a seasoned pharmaceutical executive with a strong track record of successful commercial leadership experience
GlobeNewsWire • May 4, 2026

Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer
Mr. Staab has over 25 years of financial and executive experience across the healthcare industry CHAPEL HILL, N.C., April 22, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today the appointment of Thomas R.
GlobeNewsWire • Apr 22, 2026

Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Achieved randomization target of 230 patients in LEVEL study, topline data expected in third quarter of 2026 Initiated global Phase 3 LEVEL-2 clinical trial and opened long-term OLE study for patients to remain on drug CHAPEL HILL, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, reported today financial results for the year ended December 31, 2025 and provided an update on its recent corporate progress.
GlobeNewsWire • Mar 10, 2026

Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference
CHAPEL HILL, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today that the Company will participate in a fireside chat at the 2026 Leerink Partners Global Healthcare Conference, which is taking place from March 8-11, 2026, in Miami, FL.
GlobeNewsWire • Mar 3, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Tenax Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.